The Scholz Group

The group consist of 10 members with research background in medicine, biology, stem cell biology, tissue engineering, transplantation and laboratory engineering. Our research focused on the development of beta cell replacement therapy for type 1 diabetes and on understanding human islet cell biology.

Human islet consists mainly of insulin producing beta cells and glucagon producing alpha cells responsible for the fine-tune regulation of our glucose level in our body. The laboratory aims to improve the care for diabetic patients and has a clear and strong focus of clinical translation based on experimental research.

Along the experimental research line, the group has contributed to several studies showing that human islets can be protected from a diabetic micro-environmental stress such as inflammation and hyperglycaemia. We actively participate in European networks of leading islet laboratories that investigate and improve the methodology for the isolation process of islets from donor pancreas as documented by a series of publications. We are continuing to develop innovative approaches using 3D bioprinting technology for delivery of pancreatic islets with supporting cells that will allow us to define alternative graft sites. These studies form a basis for optimizing the design of an OoC platform for ex vivo islet survival and long-term functionality.

In the past year, the laboratory has started in collaboration with prof. Helge Ræder and Assoc. prof. Simona Chera at University of Bergen to deploy iPS technology for in vitro differentiation of human stem cells towards mature beta cells. The Scholz lab. is advancing this research further in the newly UiO:Life Science funded project «Artificial Biomimetic systems – the Niche of Islet Organoids (ABINO)» that joins researchers from three Centres of Excellence (CoE) (RITMO, HTH, CCSE).

 

Selected Publications

Published Feb. 19, 2018 11:17 AM - Last modified May 19, 2020 12:50 PM